NCT02432274: A reported trial by Eisai Limited
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02432274 |
|---|---|
| Title | Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Dec. 29, 2014 |
| Completion date | July 18, 2019 |
| Required reporting date | July 17, 2020, midnight |
| Actual reporting date | July 17, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |